CN102089304A - 作为m3毒蕈碱性受体拮抗剂的奎宁环衍生物 - Google Patents

作为m3毒蕈碱性受体拮抗剂的奎宁环衍生物 Download PDF

Info

Publication number
CN102089304A
CN102089304A CN2008801303428A CN200880130342A CN102089304A CN 102089304 A CN102089304 A CN 102089304A CN 2008801303428 A CN2008801303428 A CN 2008801303428A CN 200880130342 A CN200880130342 A CN 200880130342A CN 102089304 A CN102089304 A CN 102089304A
Authority
CN
China
Prior art keywords
phenyl
bicyclo
cycloheptanecarbonyloxy
azonium
octane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801303428A
Other languages
English (en)
Chinese (zh)
Inventor
罗南.L.福特
安德鲁.N.马瑟
安东尼奥.梅特
理查德.J.布尔
伊莉莎白.A.斯基德莫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmagen Therapeutics Synergy Ltd
AstraZeneca AB
Original Assignee
Pulmagen Therapeutics Synergy Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmagen Therapeutics Synergy Ltd, AstraZeneca AB filed Critical Pulmagen Therapeutics Synergy Ltd
Publication of CN102089304A publication Critical patent/CN102089304A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
CN2008801303428A 2008-05-13 2008-05-13 作为m3毒蕈碱性受体拮抗剂的奎宁环衍生物 Pending CN102089304A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2008/001647 WO2009138707A1 (en) 2008-05-13 2008-05-13 Quinuclidine derivatives as muscarinic m3 receptor antagonists

Publications (1)

Publication Number Publication Date
CN102089304A true CN102089304A (zh) 2011-06-08

Family

ID=40361403

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801303428A Pending CN102089304A (zh) 2008-05-13 2008-05-13 作为m3毒蕈碱性受体拮抗剂的奎宁环衍生物

Country Status (17)

Country Link
US (2) US8329729B2 (https=)
EP (1) EP2300464A1 (https=)
JP (1) JP4837800B2 (https=)
CN (1) CN102089304A (https=)
AU (1) AU2008356409B2 (https=)
BR (1) BRPI0822693A2 (https=)
CA (1) CA2723981A1 (https=)
CL (1) CL2009001137A1 (https=)
EA (1) EA017627B1 (https=)
EC (1) ECSP10010606A (https=)
HN (1) HN2010002403A (https=)
IL (1) IL209126A0 (https=)
MX (1) MX2010012189A (https=)
NI (1) NI201000195A (https=)
NZ (1) NZ589091A (https=)
WO (1) WO2009138707A1 (https=)
ZA (1) ZA201007988B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103265478A (zh) * 2013-05-20 2013-08-28 中国人民解放军第二军医大学 巯基烟酸类化合物及其制备方法
CN114716380A (zh) * 2022-04-01 2022-07-08 新乡医学院 一种高效相转移催化的4-取代吡唑酮类化合物不对称氟化方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807670A (en) * 1995-08-14 1998-09-15 Abbott Laboratories Detection of hepatitis GB virus genotypes
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
CN102088976B (zh) * 2008-05-13 2012-12-26 阿斯利康(瑞典)有限公司 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
EA017627B1 (ru) 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
WO2025171311A1 (en) * 2024-02-09 2025-08-14 University Of Florida Research Foundation, Incorporated Aryl and pyridyl amide pesticides and compositions thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62140C (https=) * 1942-12-16
DE2104179C3 (de) 1971-01-29 1980-10-02 Knoll Ag, 6700 Ludwigshafen exo-2-Phenyl-bicyclo- [2,2,1] -heptan-2- (N-methylpiperidol-4)-carbonsäureester und dessen Salze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel
FR2155927A1 (en) 1971-10-15 1973-05-25 Synthelabo 1-phenylcyclo hexane carboxylic acid esters - with antispasmodic and anticholinergic activity
FR2168881A1 (en) 1972-01-25 1973-09-07 Synthelabo Tropanol 1-phenylcycloalkane carboxylic ester salts - spasmolytics and cholinergics
FR2208649A1 (en) 1972-12-01 1974-06-28 Synthelabo 1-(2-Thienyl)cycloalkane carboxylic ester salts - with spasmolytic and anticholinergic activity
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9003057D0 (sv) 1990-09-26 1990-09-26 Astra Ab New process
SK4699A3 (en) 1996-07-29 2000-04-10 Pharmacia & Upjohn Ab Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation
DK0937041T3 (da) 1996-11-11 2003-08-11 Christian R Noe Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
IL156558A0 (en) 2000-12-28 2004-01-04 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
JP2004532874A (ja) 2001-04-03 2004-10-28 アリックス セラピューティクス 抗コリン作用性化合物および使用法
PT1383786E (pt) 2001-04-30 2008-12-30 Glaxo Group Ltd Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
DE10216333A1 (de) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
EP1556034B1 (en) 2002-10-11 2008-04-16 Pfizer Limited Indole derivatives as beta-2 agonists
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
PE20050231A1 (es) 2003-06-24 2005-05-20 Novartis Ag Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
EP1684767A1 (en) 2003-11-03 2006-08-02 Norton Healthcare Limited Soft steroid compositions for use in dry powder inhalers
JPWO2006025324A1 (ja) 2004-08-30 2008-05-08 小野薬品工業株式会社 トロパン化合物およびそれらを有効成分として含有する医薬組成物
EP1797040A1 (en) 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP1807391A4 (en) 2004-10-29 2010-01-06 Astrazeneca Ab NOVEL SULFONAMIDE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND FOR THE TREATMENT OF INFLAMMATORY DISEASES
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
TW200722418A (en) 2005-04-20 2007-06-16 Astrazeneca Ab Novel compounds
EP1912942A1 (en) 2005-08-01 2008-04-23 AstraZeneca AB Novel piperidine derivatives as chemokine receptor modulators useful for the treatment of respiratory diseases.
TW200738635A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
US20090182033A1 (en) 2005-12-16 2009-07-16 Argenta Discovery Ltd. Cyclic Amine Derivatives and Their Uses
WO2007123465A1 (en) 2006-04-24 2007-11-01 Astrazeneca Ab New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder
BRPI0714463A2 (pt) 2006-07-19 2013-04-02 Astrazeneca Ab compostos de espiropiperidina tricÍclicos, sua sÍntese e seus usos como moduladores de atividade receptora de quimiocina
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
JP2010501533A (ja) 2006-08-21 2010-01-21 アージェンタ ディスカバリー リミテッド Ｍ３レセプター調節物質として有用な窒素含有複素環化合物
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2008059239A1 (en) 2006-11-14 2008-05-22 Astrazeneca Ab Novel compounds 514
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
AU2007336054A1 (en) 2006-12-19 2008-06-26 Astrazeneca Ab Quinuclidinol derivatives as muscarinic receptor antagonists
WO2008075006A1 (en) 2006-12-19 2008-06-26 Astrazeneca Ab Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
WO2008096093A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses
WO2008096094A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Bicyclor[2.2.1]hept-7-ylamine derivatives as muscarinic m3 receptor modulators
GB0702414D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Oxazole and thiazole derivatives and their uses 2
GB0702382D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New salt
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702416D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
BRPI0807004A2 (pt) 2007-02-07 2014-04-15 Argenta Discovery Ltd Sal
GB0702385D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
KR20090110353A (ko) 2007-02-15 2009-10-21 아젠터 디스커버리 리미티드 Ｍ３ 무스카린 수용체로서의 헤테로시클릭 유도체
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
WO2008149053A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Ltd. Bicycl0 [2. 2. 1] he pt- 2-ylamine derivates and their use
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
WO2009098453A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
WO2009098455A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease
HRP20120968T1 (hr) 2008-02-06 2013-01-31 Astrazeneca Ab Spojevi
EA017627B1 (ru) 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
GB0808707D0 (en) 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
CN102088976B (zh) 2008-05-13 2012-12-26 阿斯利康(瑞典)有限公司 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
GB0808709D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
GB0811100D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination
GB0811099D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
WO2009153536A1 (en) 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
CA2733449A1 (en) 2008-08-12 2010-02-18 Astrazeneca Ab 2-hydroxy-ethanesulfonate salt
WO2010018352A1 (en) 2008-08-12 2010-02-18 Argenta Discovery Limited Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
GB0814729D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103265478A (zh) * 2013-05-20 2013-08-28 中国人民解放军第二军医大学 巯基烟酸类化合物及其制备方法
CN103265478B (zh) * 2013-05-20 2015-09-30 中国人民解放军第二军医大学 巯基烟酸类化合物及其制备方法
CN114716380A (zh) * 2022-04-01 2022-07-08 新乡医学院 一种高效相转移催化的4-取代吡唑酮类化合物不对称氟化方法
CN114716380B (zh) * 2022-04-01 2024-06-21 新乡医学院 一种相转移催化的4-取代吡唑酮类化合物不对称氟化方法

Also Published As

Publication number Publication date
US8329729B2 (en) 2012-12-11
HN2010002403A (es) 2013-01-28
US20110172237A1 (en) 2011-07-14
EA201001645A1 (ru) 2011-06-30
US20130030001A1 (en) 2013-01-31
ECSP10010606A (es) 2010-12-30
WO2009138707A1 (en) 2009-11-19
MX2010012189A (es) 2011-03-02
JP2011520853A (ja) 2011-07-21
IL209126A0 (en) 2011-01-31
JP4837800B2 (ja) 2011-12-14
WO2009138707A9 (en) 2010-01-28
EP2300464A1 (en) 2011-03-30
BRPI0822693A2 (pt) 2015-07-07
AU2008356409A1 (en) 2009-11-19
NZ589091A (en) 2011-07-29
CA2723981A1 (en) 2009-11-19
ZA201007988B (en) 2011-07-27
CL2009001137A1 (es) 2009-11-27
AU2008356409B2 (en) 2012-01-19
EA017627B1 (ru) 2013-01-30
NI201000195A (es) 2012-08-16

Similar Documents

Publication Publication Date Title
RU2456286C2 (ru) Хинуклидиновые производные (гетеро)арилциклогептанкарбоновой кислоты в качестве антагонистов мускариновых рецепторов
JP4604129B2 (ja) ムスカリン受容体アンタゴニストとしてのキヌクリジノール誘導体
CN102089304A (zh) 作为m3毒蕈碱性受体拮抗剂的奎宁环衍生物
CN101679275B (zh) 异喹诺酮衍生物及其药学上的应用
JP2009534463A (ja) 例えば慢性気管支閉塞、喘息および過活動膀胱の処置に有用な、ムスカリンｍ３受容体アンタゴニスト活性を有する環状アミノアルコールの新規アルキルエステル
WO2008059239A1 (en) Novel compounds 514
WO2008075006A1 (en) Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)
CN101535306B (zh) 作为毒蕈碱受体拮抗剂的（杂）芳基环庚基甲酸的奎宁环衍生物
CN101490003A (zh) 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
JP2011195593A (ja) ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
HK1158205A (en) Quinuclidine derivatives as muscarinic m3 receptor antagonists
ES2357988T3 (es) Derivados de quiniclidina de ácido(hetero)arilcicloheptanocarboxílico como antagonistas del receptor muscarínico.
HK1148001A (en) Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists
HK1134091B (en) Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1158205

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110608

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1158205

Country of ref document: HK